In the C38 tumor model, high antitumor activity was observed for domatinostat and domatinostat+anti-PD-1 combination therapy, whereas anti-PD-1 alone did not significantly reduce tumor volumes (Fig. 5a). This evidence concerns the gene PDCD1 and neoplasm.